MedTrace Logo

Ophthalmic Solution in Diabetic Corneal Alteration

NCT06573606 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-08-29

No results posted yet for this study

Summary

Data analyses and revision of the DED symptoms in diabetic subjects. A novel ophthalmic solution containing cross-linked ha (CX-HA) and Chondroitin sulphate (CS) has been made available on the market.

Both molecules have been widely studied for their viscoelastic and hydrating properties.

Nevertheless, the use of CS in ophthalmology has been limited since, routinely, the molecule is of animal origins.

This new ophthalmic solution is the first on the market formulated with a CS of non-animal origin.

Conditions

  • Dry Eye Disease (DED)

Interventions

DEVICE

CX-HA and CS

Sterile Isotonic ophthalmic solution

Sponsors & Collaborators

  • San Giovanni Addolorata Hospital

    collaborator OTHER

  • D&V FARMA srl

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573606 on ClinicalTrials.gov